bpc-157 clinical trial human dosing Dosage Protocol: Injection Guide bpc 157 human clinical trial

At day 13, the gingivomucosal tissues encircling the molars were removed on both sides

Both are dosed subQ Same daily injection schedule No known stability conflict Synergistic: BPC-157 targets soft tissue (tendons, gut, ligaments), TB-500 (thymosin beta-4) addresses systemic healing and mobility Draw BPC-157 first, then TB-500 into the same syringe

Clinical insight: European Journal of Pharmacology (2023) found BPC-157 significantly reduced tissue necrosis and vascular damage in ischemic injury models

Surgery is a stress

Some clients chose a weekly shot then go onto monthly while others get one whenever they feel the need